Quick Answer
enGene Therapeutics Inc. reported Cash and Equivalents of $50.15 million for fiscal year 2025.
enGene Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $50.15M | -71.0% |
| 2024 | $173.00M | +112.2% |
| 2023 | $81.52M | +298.9% |
| 2022 | $20.43M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $36.61M | -41.3% | -27.0% |
| October 31, 2025 | $50.15M | -71.0% | +53.7% |
| July 31, 2025 | $32.62M | -87.3% | -43.3% |
| April 30, 2025 | $57.55M | -78.3% | -7.7% |
| January 31, 2025 | $62.35M | -27.2% | -64.0% |
| October 31, 2024 | $173.00M | +112.2% | -32.9% |
| July 31, 2024 | $257.68M | — | -2.7% |
| April 30, 2024 | $264.81M | — | +209.2% |
- enGene Therapeutics Inc. showed a decrease of -71.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s cash and equivalents has grown by 145.4% (from $20.43 million to $50.15 million).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: